dnx-2440
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 7, 2018 (NCT03714334)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Gastrointestinal Stromal Tumors · Phase 1
- Glioblastoma · Phase 1
- Liver Neoplasms · Phase 1
- Melanoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Sarcoma · Phase 1
- Stomach Neoplasms · Phase 1
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04714983 | Phase 1 | Feb 15, 2021 | DNAtrix, Inc., University of South Florida |
| NCT03714334 | Phase 1 | Nov 7, 2018 | Clinica Universidad de Navarra, DNAtrix, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DNAtrix, Inc. | For profit | 2 | 1 | 1 | 2018 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1